ShareValue scores for APN.JSE: Valuation 53, Quality 38, Growth 17, Health 27.

APN.JSE
JSE

Aspen Pharmacare Holdings Ltd

ZAR 152.35(+3.09%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

1% to 15%
Valuation
53
Fair Value
Price vs Value
Quality
38
Weak
Business Strength
Growth
17
Weak
Revenue & Earnings
Health
27
Stressed
Financial Stability
Momentum
71
Bullish
Price Trend

Company Details

About

Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and markets specialty and branded pharmaceutical products in Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers injectables for therapeutic areas, such as anaesthetics, anticoagulants, antithrombotic agents, analgesics, and hormone replacement medicines under the Arixtra, Diprivan, Fraxiparine, Marcaine, Sustanon, and Xylocaine brands; over-the-counter medicines under the Emla, Maltofer, Ovestin, Solpadeine, and Xylocaine brands; and prescription products for anti-inflammatories, immunosuppressants, hypothyroidism, anti-gout, analgesics, and corticosteroids under the Eltroxin, Imuran, Lipitor, Lyrica, and Zyloric brands. It also manufactures active pharmaceutical ingredients, finished dose forms, and heparins, as well as steriles, oral solid doses, liquids, semi-solids, and biologicals. The company exports its products. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026